The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease
About this study
The participant in this study includes Alzheimer's disease (AD including familial AD and sporadic AD) patients, amnestic mild cognitive impairment (aMCI) patients, non-AD dementia patients and cognitively normal control. The purpose of this study is to establish the best cut-off value of cerebrospinal fluid (CSF) and blood β-amyloid (Aβ) 42/40, total tau (t-tau) , phosphorylated tau ,inflammatory factors, etc. in diagnosis of Alzheimer's disease (AD).
- Condition
- Alzheimer's Disease
- Sponsor
- Capital Medical University
Who can join
- Age
- 55 to 75 years
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 8
- Minimum age: 55 years
- Maximum age: 75 years
- Study condition: Alzheimer's Disease
- Written informed consent obtained from participant or legal guardian prior to any study-related procedures.
- The diagnosis of AD is made using the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.
- The diagnosis of aMCI is assigned according to 2004 Petersen criteria.
- As for non-AD dementia, the McKeith criteria are used for DLB, the revised diagnostic criteria proposed by the International bvFTD Criteria Consortium for behavioral variant FTD, the Gorno-Tempini criteria for the semantic variant FTD or non-fluent aphasia, the Movement Disorder Society Task Force criteria for PDD, the vascular behavioral and cognitive disorders (Vas-Cog) criteria for VaD, the Armstrong's criteria for CBD, the CDC's diagnostic criteria for CJD, etc.
- In addition, normal cognition is supported by MMSE, CDR and other cognitive function scales.
Exclusion 1
- Other medical or psychiatric illness. No one can serve as an informant. Refused to complete a cognitive test and provide biospecimen.
Where
1 site, 1 recruiting
Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, China
Contact
-
Jianping Jia, Doctor
8610-83199449 jiajp@vip.126.com
Potential match only. Final eligibility is determined by the study team.